Medicine and Dentistry
Inflammatory Bowel Disease
100%
Crohn's Disease
46%
COVID-19
42%
Infliximab
39%
Ulcerative Colitis
38%
Diseases
35%
Severe Acute Respiratory Syndrome Coronavirus 2
23%
Infection
19%
Patient with Crohn's Disease
18%
Bifidobacterium
16%
Therapeutic Drug Monitoring
16%
Clinical Trial
15%
Biological Product
15%
Health Care Cost
15%
Irritable Bowel Syndrome
14%
Low FODMAP Diet
14%
Biosimilar
14%
T Cell
14%
Small Intestine
14%
Endoscopy
12%
Gut Microbiota
11%
Observational Study
9%
Maintenance Therapy
9%
Adalimumab
9%
Antibody Response
9%
Biopsy Technique
8%
Enzyme Linked Immunosorbent Assay
8%
Personalized Medicine
8%
Clinician
8%
Quality of Life
8%
Gene Expression
7%
Cohort Analysis
7%
Systematic Review
7%
Regulatory T Cell
7%
Checklist
7%
Granulomatosis
7%
Clinical Research
7%
Cardiogenic Shock
7%
Mental Health
7%
Convalescence
7%
Cohort Study
7%
Advanced Therapy
7%
Fecal Microbiota Transplantation
7%
Vedolizumab
7%
Tumor Necrosis Factor
7%
Prebiotics
7%
Butyrophilin
7%
Golimumab
7%
Immunogenicity
7%
Galactose Oligosaccharide
7%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
80%
Crohn's Disease
53%
Ulcerative Colitis
46%
Infliximab
34%
Remission
33%
Mercaptopurine
28%
Adalimumab
23%
Therapeutic Drug Monitoring
22%
Ustekinumab
22%
Diseases
20%
Biological Product
20%
Colitis
15%
SARS Coronavirus
15%
Enzyme-Linked Immunosorbent Assay
14%
Feces microflora
14%
COVID-19 Vaccine
14%
Case-Control Study
14%
Tofacitinib
13%
Drug Concentration
13%
Tumor Necrosis Factor
12%
Immunogenicity
10%
Pandemic
10%
Clinical Trial
10%
Inflammation
8%
Janus Kinase Inhibitor
8%
Calgranulin
8%
Cohort Study
8%
Disease Activity
7%
Infection
7%
Adult Respiratory Distress Syndrome
7%
Intestine Flora
7%
Campylobacter Enteritis
7%
Granulomatosis
7%
Golimumab
7%
Vasoactive Intestinal Polypeptide
7%
Ileitis
7%
Biosimilar Agent
7%
Tioguanine
7%
Clinical Research
7%
Clostridium Difficile Infection
7%
Galactose Oligosaccharide
7%
Monotherapy
6%
Tumor Necrosis Factor Inhibitor
6%
Drug Antibody
6%
Immunomodulating Agent
5%
Immunology and Microbiology
Inflammatory Bowel Disease
65%
Infliximab
63%
Severe Acute Respiratory Syndrome Coronavirus 2
44%
Crohn's Disease
31%
Antibody Response
30%
COVID-19
28%
T Cell
22%
Vedolizumab
21%
Adalimumab
21%
Regulatory T Cell
19%
Adoptive Immunity
14%
Biosimilar Agent
14%
Feces microflora
14%
Drug Concentration
13%
Antibody Blood Level
11%
Tofacitinib
9%
Breakthrough Infection
8%
Wild Type
8%
Immunogenicity
7%
Ulcerative Colitis
7%
Integrin
7%
Immunoglobulin E
7%
Autoimmunity
7%
Omicron Coronavirus Variant
7%
Neutralizing Antibody
7%
Virus Type
7%
Golimumab
7%
Campylobacter Jejuni
7%
Enhancer Region
7%
Blood Level
7%
Interleukin 2
7%
Peptoclostridium difficile
7%
Cell Selection
7%
Spike
6%
Tumor Necrosis Factor Alpha
5%
Ustekinumab
5%
Enzyme-Linked Immunosorbent Assay
5%